Nouscom
Clinical-stage immuno-oncology company developing novel virus-based immunotherapies and personalized cancer vaccines designed to generate potent and durable anti-tumor T cell responses.
Website
https://nouscom.comLocation
Basel, Switzerland & Rome, Italy
Founded
2015
Investors
1
Categories
biotech, oncology, immunotherapy, cancer-vaccines
Notes
Nouscom is a clinical-stage immuno-oncology company focused on developing novel virus-based immunotherapies for cancer treatment. The company's proprietary platform is designed to generate potent and durable anti-tumor T cell responses using viral vector technology and personalized neoantigen cancer vaccines.
Nouscom's approach combines adenovirus-based vector platforms with personalized cancer vaccine technology to activate the patient's immune system against tumors.
Team
- Elisa Scarselli, Ph.D. - Co-Founder & Chief Scientific Officer
- Alfredo Nicosia, Ph.D. - Co-Founder
Additional Research Findings
- Founded in 2015 with headquarters in Basel, Switzerland and Rome, Italy
- Portfolio company of Angelini Ventures (2024)
- Proprietary viral vector technology platform for cancer immunotherapy
- Focus on personalized neoantigen-based cancer vaccines
- Developing therapies designed to enhance T cell responses against tumors
- Multiple clinical programs in oncology
- European biotech with global development ambitions
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Angelini Ventures | Rome, Italy | cvc | seedseries-a+2 | 4 |